Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report-Reference-Cited by-同舟云学术

Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report

Published:2020-03 Issue:2 Volume:21 Page:e78-e83
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Zhang Yi,Yu Min,Yuan Mingming,Chen Rongrong,Huang Mei-Juan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001;Shaw;Ann Oncol,2019

2. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer;Wu;J Clin Oncol,2018

3. Different types of ROS1 fusion partners yield comparable efficacy to crizotinib;He;Oncol Res,2019

4. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer;Zhang;J Immunother Cancer,2019

5. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS;Wang;Mod Pathol,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fusion Genes Landscape of Lung Cancer Patients From Inner Mongolia, China;Genes, Chromosomes and Cancer;2024-07

2. Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study;Lung Cancer;2023-07

3. Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion;Frontiers in Oncology;2022-03-01

4. ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date;Current Oncology;2022-01-28

5. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells;International Journal of Molecular Sciences;2022-01-04